Watch FIXX. Know when insiders buy.
One email the day a filing lands. Free.
FIXX
Q32 Bio Inc.
11.87
−0.16 −1.33%
USD · close Sep 15
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $353.4MP/E 3.8DIV YIELD —FCF YIELD —REV TTM —NET INCOME $33.8MNET CASH —52W 11.27 – 14.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$9.1M | −$8.9M | — | -0.44 | −$3.1M | — | — | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$7.7M | −$7.6M | — | -0.54 | −$6.3M | — | — | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | $45.9M | $57.7M | — | 4.71 | −$6.2M | $0 | −$6.2M | Mar 10 |
| Q3 2025 · Sep 30 | — | — | — | −$7.6M | −$7.4M | — | -0.60 | −$4.2M | $0 | −$4.2M | Nov 13 |
| Q2 2025 · Jun 30 | — | — | — | −$9.2M | −$9.5M | — | -0.78 | −$10.7M | — | — | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | −$12.2M | −$11M | −1172.0% | -0.90 | −$12.5M | — | — | Aug 5 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$14.5M | −$14.2M | — | -0.98 | −$11.4M | $2K | −$11.4M | Mar 10 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$18.8M | −$17.6M | — | -1.46 | −$19.5M | $58K | −$19.6M | Nov 13 |
| Q2 2024 · Jun 30 | $0 | — | — | −$17.9M | −$17M | — | -1.42 | −$22.2M | $15K | −$22.2M | Nov 13 |
| Q1 2024 · Mar 31 | $0 | — | — | −$14.8M | $1M | — | -6.33 | −$14.6M | $0 | −$14.6M | Nov 13 |
| Q4 2023 · Dec 31derived | −$14.7M | — | — | −$25.8M | −$27.1M | — | -77.15 | −$10.7M | $0 | −$10.7M | Mar 11 |
| Q3 2023 · Sep 30 | $1.9M | — | — | −$7.8M | −$14M | — | -40.52 | $15.9M | $1K | $15.9M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $53.7M | — | $16.9M | $29.8M | 55.5% | 2.42 | −$33.5M | $0 | −$33.5M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$66.1M | −$47.7M | — | -6.58 | −$67.7M | $75K | −$67.8M | — | — |
| FY2023 · to Dec 31 | −$6.7M | — | −$48.3M | −$53.7M | 808.0% | -153.96 | −$18.7M | $5K | −$18.7M | — | — |
| FY2022 · to Dec 31 | $3.2M | — | −$133.3M | −$5M | -156.0% | -0.09 | −$113.7M | $1.3M | −$114.9M | — | — |
| FY2021 · to Dec 31 | $34M | — | −$95.9M | −$95.8M | -281.9% | -1.73 | −$109.8M | $2.4M | −$112.1M | — | — |
| FY2020 · to Dec 31 | $2.7M | — | −$130.3M | −$128.7M | -4762.9% | -2.80 | −$94.3M | $3.7M | −$98.1M | — | — |
Every number comes from Q32 Bio Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.